Satoshi Konagai
Direktor/Vorstandsmitglied bei Solu Therapeutics
Profil
Satoshi Konagai is currently a Director at Cleave Therapeutics, Inc. and a Director at Solu Therapeutics, Inc. He is also a Senior Investment Manager at Astellas Venture Management LLC.
Previously, he worked as a Senior Manager at Astellas Pharma, Inc. from 2015 to 2020.
Mr. Konagai holds an MBA from the University of Massachusetts and both undergraduate and graduate degrees from Kyoto University.
Aktive Positionen von Satoshi Konagai
| Unternehmen | Position | Beginn |
|---|---|---|
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Private Equity Investor | 01.10.2020 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 01.12.2021 |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Satoshi Konagai
| Unternehmen | Position | Ende |
|---|---|---|
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | 31.10.2020 |
Ausbildung von Satoshi Konagai
| Kyoto University | Graduate Degree |
| University of Massachusetts | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ASTELLAS PHARMA INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Phrama Inc founded in 2000. The firm is headquartered in Brisbane, California. | Finance |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
